



US005705401A

United States Patent [19]

[11] Patent Number: **5,705,401**

Masters et al.

[45] Date of Patent: **Jan. 6, 1998**

- [54] **METHOD OF ASSAYING FOR ALZHEIMER'S DISEASE**
- [75] Inventors: **Colin Louis Masters**, Clifton Hill, Australia; **Ashley Ian Bush**, Boston, Mass.; **Konrad Traugott Beyreuther**, Heidelberg, Germany
- [73] Assignee: **The University of Melbourne**, Victoria, Australia

FOREIGN PATENT DOCUMENTS

33365/89	11/1989	Australia .
58173/90	1/1991	Australia .
A04126095	4/1992	Japan .
A04252954	9/1992	Japan .
A04252955	9/1992	Japan .
A04252956	9/1992	Japan .
WO 91/16628	10/1991	WIPO .
WO 92/00521	1/1992	WIPO .
WO 92/13069	8/1992	WIPO .

- [21] Appl. No.: **240,720**
- [22] PCT Filed: **Nov. 12, 1992**
- [86] PCT No.: **PCT/AU92/00610**
- § 371 Date: **Sep. 16, 1994**
- § 102(e) Date: **Sep. 16, 1994**
- [87] PCT Pub. No.: **WO93/10459**
- PCT Pub. Date: **May 27, 1993**

OTHER PUBLICATIONS

Selkoe et al. (1988) "β-Amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and non-neural tissues". *Proc. Natl. Acad. Sci.*, 85:7341-7345.

Horns et al. *Neurology* 1989; 39:1159-1165 "The Consortium to Establish a Registry fo Alzheimer's Disease".

Bush et al. *J. Biol. Chem.* Sep. 15, 1990; 265(26):15977-15983 "The Amyloid Precursor Protein of Alzheimer's Disease is Released by Human Platelets".

[30] Foreign Application Priority Data

Nov. 12, 1991	[AU]	Australia	PK 9438
Jul. 8, 1992	[AU]	Australia	PL 3374

Primary Examiner—Marian C. Knode
Assistant Examiner—Patricia A. Duffy
Attorney, Agent, or Firm—Scully, Scott, Murphy & Presser

- [51] Int. Cl.⁶ **G01N 33/543; G01N 33/544; G01N 33/545**
- [52] U.S. Cl. **436/518; 436/530; 436/531; 436/811**
- [58] Field of Search **435/7.1, 7.94, 435/975; 436/811, 530, 531, 518; 530/350**

[57] ABSTRACT

The present invention relates to a method of assaying for Alzheimer's disease in a human by determining the relative abundance of one or more forms of amyloid precursor protein (APP) or the enzyme responsible for said forms in circulatory fluid and to a method for treating the disease by modulating divalent cation, trivalent cation and/or heparin interaction with APP.

[56] References Cited

U.S. PATENT DOCUMENTS

4,281,061	7/1981	Zuk et al.	435/7
5,234,814	8/1993	Card et al.	435/7.21

3 Claims, 10 Drawing Sheets